Abstract Library

#1225 Everolimus in Patients (pts) with Advanced Lung Carcinoids: Evaluation of Median Progression Free Survival (PFS) and Median Time to First Dose Decrease or Discontinuation (DDD)

Introduction: Treatment of well-differentiated (WD) lung neuroendocrine tumors (NETs) is challenging. Everolimus (mTOR inhibitor) has shown encouraging results in digestive NETs but data about its activity on lung carcinoid are sparse.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Gianoncelli L, Guigay J, Caramella C, Borget I, Mir O,

Keywords: lung carcinoid, everolimus, mTOR inhibitor,

#998 Intra and Interobserver Reproducibility of CT and MRI for Measurement of Liver Metastasis as a Basis of RECIST Evaluation in Patients with Neuroendocrine Tumors

Introduction: The reliability of RECIST evaluation in patients with NET has not yet been analyzed.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Arfi Rouche J, Foulon S, Caramella C, Ternes N, Planchard D,

Keywords: CT, MRI, liver, metastasis, reproducibility, RECIST,

#759 Inter-and Intra-Observers Reproducibility of MRI for the Measurement of NET Liver Metastases

Introduction: Assessment of treatment is based on metastases size measurement.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Arfi Rouche J

Authors: Arfi Rouche J, Caramella C, Foulon S, Laplanche A, Baudin E,

Keywords: neuroendocrine, MRI, liver, metastase, reproducibility,

#706 Is There a Therapeutic Impact of Segmental Portal Hypertension on Advanced Pancreatic Neuroendocrine Tumors?

Introduction: Well-differenciated locally advanced Pancreatic Neuroendocrine Tumors (PNET) lead to significant local complications due to segmental portal hypertension (SPH).

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Dumont F

Authors: Goudard Y, Dumont F, Caramella C, Goéré D, Honoré C,

Keywords: pancreatic neuroendocrine tumors, segmental portal hypertension, locally advanced,

#322 Effect of mTOR Inhibitor and Octreotide LAR on the Vascularization of Hepatic Metastases of Non-Pancreatic NETs: Preliminary Semi-Quantitative Dynamic MRI Assessment

Introduction: mTOR inhibitor Everolimus is a promising treatment in advanced NET. Its mechanisms include an antiangiogenic effect. Dynamic-enhanced MRI (D-MRI) enables the in vivo evaluation of tumoral perfusion.

Conference: 8th Annual ENETSConcerence (2011)

Presenting Author:

Authors: Pham C, E. B, C. C, J. G, F. B,

Keywords: neuroendocrine tumor, mTOR, everolimus, octreotide, vascularisation, MRI,